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Natural killer (NK) cells derived from the human female reproductive tract (FRT) are phenotypically and
functionally distinct from those obtained from peripheral blood. Because the FRT is a primary site of human
immunodeficiency virus type 1 (HIV-1) infection in women, we determined whether soluble factors secreted by
uterine-derived NK (uNK) cells inhibit HIV-1 infection. Clonal populations of uNK cells were activated with
interleukin-12 (IL-12) and IL-15, and conditioned media (CM) from these cultures evaluated for their ability
to inhibit infection of cells by HIV-1IIIB, HIV-1NL4.3, and HIV-1HC4 (X4-tropic) or HIV-1BaL (R5-tropic) viruses.
We found that soluble factors secreted by activated uNK cells significantly inhibited X4-tropic virus infection
of TZM-bl cells, peripheral blood mononuclear cells, and primary human endometrial cells, but not infection
by HIV-1BaL. In contrast, CM from peripheral blood NK (bNK) cells did not inhibit HIV-1 infection of cells.
Analysis of factors secreted from uNK clones with anti-HIV-1 activity demonstrated significantly higher levels
of CXCL12 compared to uNK clones without this activity, and the HIV inhibitory activity was neutralized by
antibodies to CXCL12. Collectively, these data demonstrate that human uNK cells release chemokines with
anti-HIV-1 activity for X4-tropic strains and this suggest that these chemokines may contribute to the
inhibition of X4-tropic strain transmission across mucosal tissues.
Natural killer (NK) cells play a pivotal role in the innate immune defense against tumors and in the killing of virus-infected
cells (45). In the peripheral blood, NK cells account for ⬃10% of
mononuclear cells and are subdivided into two groups based on
CD56 and CD16 surface expression (35, 40). The CD56dim
CD16⫹ subtype comprises the majority of blood NK (bNK) cells
and are highly cytolytic, whereas the CD56bright CD16⫺ subset
accounts for ⬍10% of bNK cells, are less cytolytic, and are primarily cytokine producers (11, 39). In the female reproductive
tract (FRT), however, NK cells form a large population of the
resident leukocytes, with an even higher proportion found during
the second half (secretory phase) of the menstrual cycle (21, 23,
24, 31). The phenotype of NK cells in the FRT is more similar to
the CD56bright CD16⫺ bNK cell subset. However, in contrast to
bNK cells, FRT NK cells are unique in that they express CD9 and
CD69 and are much larger and granular than bNK cells (31). The
differences between bNK cells and those in the FRT are perhaps
largely due to the microenvironment in which they reside, including exposure to fluctuations in steroid sex hormones throughout
the menstrual cycle, as well as to inflammatory cytokines and
chemokines secreted by innate and acquired immune cells in
response to microbial exposure within this site (33).
bNK cells play an important role in protection against human immunodeficiency virus (HIV). This is either directly,
through antibody-dependent cell-mediated cytotoxicity (2, 18,
38, 43), or indirectly, through the production of chemokines;

CC-chemokine ligand 3 (CCL3; also called MIP-1␣), CCL4
(MIP1-␤), and CCL5 (RANTES), which are natural ligands of
CCR5 (10) and which block viruses that utilize the CCR5
coreceptor for entry (5, 6, 9, 13, 16, 26). NK cells also produce
cytokines, including gamma interferon (IFN-␥), granulocyte/
macrophage colony-stimulating factor, and tumor necrosis factor alpha which can suppress HIV replication by recruiting
other effector cells (16). Studies have shown that bNK cells
from uninfected HIV-exposed individuals produce significantly
larger amounts of IFN-␥ than HIV-infected individuals, indicating that IFN-␥ could have some protective role (30, 37). The
ability of uterine-derived NK (uNK) cells to inhibit HIV-1
infection is unknown.
Because the major route of HIV-1 transmission in women
occurs across the mucosal surfaces of the FRT, we sought to
determine whether uNK cells play a role in protection against
HIV-1 infection. Mucosal NK cells have unique properties compared to bNK cells. Recently, a subset of mucosal NK cells found
in tonsils and gut has been described that produce interleukin-22
(IL-22) and that may be important for protection from bacterial
infection (8, 36). Thus, the unique microenvironment of different
tissues may lead to differentiation of NK cells to express effector
functions not found in bNK cells. This study demonstrates that
uNK cells have the ability to inhibit HIV-1 infection of cells, and
this may play an important role in protection of mucosal surfaces
from infection by X4-tropic strains of HIV-1.
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Human subjects and cell isolation. uNK cells were isolated from human
endometrial tissue samples obtained from women aged between 32 to 55 years
undergoing hysterectomy for benign gynecological indications, such as prolapse
or fibroids, at the Dartmouth Hitchcock Medical Center, Lebanon, NH. Briefly,

MATERIALS AND METHODS

11188

VOL. 83, 2009
endometrial tissues were minced and digested with a cocktail of 0.01% DNase 1
and 0.1% type IV collagenase enzymes (Sigma-Aldrich, St. Louis, MO) at 37°C
in Dulbecco’s modified Eagle’s medium–F-12 (Invitrogen, Carlsbad, CA) for 1 h.
For primary endometrial cell isolation, the digested tissues were passed through
a 100-m cell strainer to facilitate dispersion into single-cell suspensions consisting of leukocytes, epithelial cells, and stromal fibroblasts. bNK cells were
isolated from peripheral blood mononuclear cell (PBMC) samples obtained
from the same patient or from healthy individuals. PBMCs were separated on
Lymphoprep gradients according to protocols provided by the manufacturer
(Axis Shield, Oslo, Norway). Institutional Review Board approval and informed
consent were obtained before tissue and blood donation.
Generation of NK cell clones. Enzymatically isolated endometrial cells were
cultured in 500 IU recombinant IL-2 (rIL-2)/ml (National Cancer Institute,
Bethesda, MD) in complete medium (RPMI 1640 supplemented with 50 M
2-mercaptoethanol [Sigma-Aldrich, St. Louis, MO], 100 U/ml penicillin, 100
g/ml streptomycin, and 1 mM sodium pyruvate [Mediatech, Manassas, VA], 0.1
mM nonessential amino acids [Invitrogen, Carlsbad, CA], and 5% human serum), for 2 to 3 days to allow for the recovery of cells following digestion. uNK
and bNK cells were purified from endometrial single-cell suspensions and
PBMCs, respectively, by negative selection using a human NK cell enrichment
cocktail containing a combination of biospecific TAC-bound antibodies directed
against CD3, CD4, CD19, CD66b, glycophorin A, and dextran (Stem Cell Technologies, Vancouver, BC, Canada), according to the manufacturer’s instructions.
The remaining (negatively selected) cells were highly enriched for NK cells as
determined by flow cytometric analysis using antibodies to CD56. These cells
were cloned using standard NK cell cloning procedures as previously described
(7, 15). Briefly, sorted uNK cells were plated at 1 to 3 cells/well in U-bottom
96-well plates together with irradiated (100 Gy) feeder cells (5 ⫻ 104 allogeneic
PBMCs together with 5 ⫻ 103 RPMI 8866 cells), supplemented with 1 g/ml
phytohemagglutinin (PHA), and 500 U rIL-2. After 10 to 14 days, the wells were
examined for growth of clones. Cells from positive wells were expanded further
and maintained in 500 U IL-2/ml for the remainder of their culture. In some
cases, primary uNK cells were expanded in IL-2 for 5 to 8 days and analyzed for
anti-HIV activity and cytokine production. These primary expanded uNK cells
represent the uNK cells from these donors.
Antibodies and reagents. The antibodies used in this study for flow cytometric
analysis of NK clones included allophycocyanin-conjugated anti-CD3, rhodamine-phycoerythrin-conjugated anti-CD56, and mouse immunoglobulin G1
(IgG1) isotype control (Invitrogen, San Jose, CA); fluorescein isothiocyanateconjugated anti-CD4, CD16, anti-CD69, anti-CD94, anti-NKB1, and antiCD158b (BD Pharmingen, San Jose, CA); and CXCL12 and goat IgG (R&D
Systems, Minneapolis, MN).
Flow cytometry. To determine the purity of NK clones before use, NK clones
were incubated with allophycocyanin-conjugated anti-CD3 and rhodamine-phycoerythrin-conjugated anti-CD56 antibodies. FACSCalibur and FACSCanto
flow cytometers were used for analysis of cell surface expression and purity of NK
clones.
Preparation of uNK and bNK CM. uNK and bNK clones were cultured in
quadruplicate wells at 105 cells/well in microtiter plates. Cells were stimulated by
incubation with IL-12 (10 ng/ml) and IL-15 (100 ng/ml) or were left unstimulated. Cell-free conditioned media (CM) from these cultures were harvested
after 72 h and stored at ⫺20°C until further analysis.
Determination of anti-HIV activity. To test the NK cell CM for anti-HIV-1
activity, the viruses used were HIV-1IIIB and HIV-1BaL (provided by Phalguni
Gupta at University of Pittsburgh), HIV-1NL4-3 (provided by John Kappes, University of Alabama at Birmingham), and HIV-1HC4 (provided by Ruth Connor,
Dartmouth Medical School). We used the TZM-bl indicator cell line (NIH AIDS
Research & Reference Reagent Program, Bethesda, MD), which expresses CD4,
CXCR4, and CCR5, and contains a ␤-galactosidase (␤-Gal) reporter gene under
the transcriptional control of the HIV-1 long terminal repeat (LTR) (44).
TZM-bl cells were seeded at a density of 2.5 ⫻ 104 cells/well in a 96-well plate.
After 24 h, 40 l of conditioned medium from either the IL-12- plus IL-15activated, or nonactivated, NK cells was added to quadruplicate wells containing
TZM-bl cells for 1 h, followed by the addition of HIV-1 at a multiplicity of
infection (MOI) of 1. After 48 h in culture, beta-glo (Promega, Madison, WI)
was added to each well. The relative light units (RLU) were detected after 1 h
of incubation using a luminometer (Turner Biosystems, Sunnyvale, CA). Inhibition that was ⬍15% was not considered to be biologically relevant.
Infection of PBMCs and FRT cells. PBMCs isolated from the hysterectomy
tissue donor or from volunteer donors and FRT cells from the endometrium
were cultured in complete medium with 1 g/ml PHA. After 2 days in culture,
cells were washed and cultured at 105 cells/well in fresh complete medium
supplemented with 10 IU/ml IL-2, with or without uNK CM at a medium/uNK

HUMAN UTERINE NK CELLS INHIBIT HIV-1

11189

CM ratio of 3:1. After 1 h, the cells were infected with HIV-1IIIB for 2 h, washed,
and returned to culture in the presence of complete medium supplemented with
IL-2. Cell-free culture supernatants were collected from the PBMC and FRT
cultures on days 3, 5, and 7 postinfection. These supernatants were then added
to cultures of TZM-bl cells for 48 h, and the ␤-Gal expression was determined as
described above.
ELISAs to detect cytokines in NK cell conditioned media. CM from control
and IL-12- plus IL-15-stimulated uNK and bNK cells were tested in triplicate for
soluble IFN-␥, CXCL12, and IL-22 by enzyme-linked immunosorbent assay
(ELISA), using human-specific Duoset ELISA development system kits (R&D
Systems, Minneapolis, MN) according to the manufacturer’s instructions.
Statistical analysis. Data are expressed as the mean ⫾ standard error of the
mean (SEM). A one-way analysis of variance with Newman-Keuls post test or a
Mann-Whitney nonparametric analysis was performed using GraphPad Prism 4
(La Jolla, CA). Statistical significance was defined as P ⬍ 0.05.

RESULTS
Human uNK cells secrete soluble factors that inhibit infection by HIV-1. We determined the ability of CM from clonal
populations of uNK cells to inhibit infection of TZM-bl cells
with either HIV-1IIIB (X4) or HIV-1BaL (R5). Cell-free media
from clonal populations of uNK cells significantly inhibited
infection of TZM-bl cells by HIV-1IIIB (P ⬍ 0.001), whereas
the same CM had no inhibitory activity against the HIV-1BaL
(P ⬎ 0.05) (Fig. 1A and B). The data shown in Fig. 1B represent results from three different experiments using seven different uNK clones obtained from four different individuals.
Similarly, CM from primary expanded uNK cells inhibited
HIV-1IIIB, but not HIV-1Bal (Fig. 1C). To assess the ability of
uNK CM to inhibit other X4-tropic strains, we compared the
inhibitory activity of uNK CM against HIV-1NL4-3 and HIV1HC4 (a primary X4 HIV-1 strain) and found that uNK cell
clones were able to reduce the infection by all X4-tropic HIV-1
strains tested (Fig. 1D). In contrast to uNK cell CM, bNK cell
CM did not mediate similar inhibition of HIV-1 infection. In
fact in side-by-side comparisons, there was no inhibition of
HIV infection by bNK cell CM. These data indicate that uNK
cells, but not bNK cells, significantly inhibited infection by all
three X4 HIV-1 strains tested.
The anti-HIV activity of uNK cells but not bNK cells is
increased by cytokine activation. NK cell effector functions are
known to be increased by cytokine activation (19), and IL-12
and IL-15, which are present within the human endometrium,
stimulate uNK cells to produce cytokines (14). The anti-HIV
activity of CM from both uNK and bNK cells was analyzed
from both stimulated and unstimulated (control) NK cells. As
shown in Fig. 2A, 64% of uNK clones showed significant inhibition of TZM-bl cell infection by HIV-1IIIB (P ⬍ 0.01). These
data represent analysis of uNK CM of 33 different clones from
15 different individuals. Approximately 40% of CM from unstimulated uNK clones demonstrated inhibition of HIV-1IIIB
infection, indicating that some uNK cells can constitutively
inhibit HIV-1. There was no correlation found between the
uNK anti-HIV activity and age of the donor (data not shown).
To establish whether bNK cell CM had similar anti-HIV activity, bNK clones from normal healthy donors or from the
blood of the hysterectomy patients were assayed for anti-HIV
activity. When 10 bNK cell clones prepared from six individuals were tested, none of the bNK clones showed anti-HIV
activity. Analysis of paired uNK clones from both cytokinestimulated and unstimulated cells showed that the anti-HIV
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FIG. 1. Human uNK cells produce soluble factors with anti-HIV activity. (A) uNK cells were cultured with or without IL-12 plus IL-15 for 3
days. The resulting cell-free uNK CM was incubated with TZM-bl cells for 1 h and then infected with HIV-1IIIB at an MOI of 1. ␤-Gal activity
was measured after 48 h. Results are means ⫾ SEM of a representative experiment in which each condition was tested in quadruplicate. Media
(open bars) and uNK CM (black bars), in the absence (⫺) or presence of HIV-1IIIB (IIIB), are shown. uNK CM significantly reduced HIV-1
infection in TZM-bl cells. ***, P ⬍ 0.001. (B) uNK CM from four different individuals in three different experiments were treated in quadruplicate
as in panel A and infected with either HIV-1IIIB or HIV-1BaL (BaL). The data are normalized to RLU from the medium-plus-virus (HIV-1IIIB or
HIV-1BaL) conditions and show that the uNK anti-HIV activity is specific for HIV-1IIIB. ***, P ⬍ 0.001 (Mann-Whitney test). Values represent
means ⫾ SEM (n ⫽ 7 different uNK clones). ns, not significant. The y axis shows RLU values, converted into percentages with media as 100%.
(C) CM from primary NK cells were treated in quadruplicate as in panel B. Data are representative of two experiments with two different
individuals. (D) TZM-bl cells were preincubated for 1 h with tissue culture media (open bars), bNK CM (hatched bars), or uNK CM (black bars).
bNK and uNK CM were prepared from the blood and endometrial tissue of the same individual. One hour later, TZM-bl cells were infected with
the indicated X4-tropic HIV-1 strains. After 48 h in culture, ␤-gal activity was measured. Data are expressed as the percentage of ␤-gal expression
relative to the media control. Values represent means ⫾ SEM, with n ⫽ 4 different clones. ***, P ⬍ 0.001 (one-way analysis of variance).

activity of uNK CM was significantly increased from stimulated
uNK cells compared to unstimulated uNK cells (P ⬍ 0.001)
(Fig. 2B). Thus, uNK cells are able to produce soluble factors
that can inhibit HIV-1 infection and this activity is increased
upon cytokine stimulation.

uNK cells secrete molecules that prevent infection of
PBMCs and primary FRT cells by HIV-1. The primary targets
of HIV-1 in vivo are CD4⫹ T cells, monocytes and macrophages, and these leukocytes are present within PBMCs and
primary human endometrium. To determine whether uNK

FIG. 2. Anti-HIV-1 activity of CM from uNK cells is increased by cytokine activation. (A) CM from uNK and bNK clones collected after 3 days
of stimulation with IL-12 and IL-15 (S) or in the absence of cytokine stimulation (U) were preincubated for 1 h with TZM-bl cells prior to the
addition of HIV-1IIIB. The percentage of inhibition of HIV-1 infection was determined by comparing RLU values with those of the medium
control. Each data point represents an individual clone, and the average of each group is shown. Stimulated uNK clones showed significantly higher
inhibition than unstimulated uNK clones (**, P ⬍ 0.01; n ⫽ 31), and CM from bNK clones did not inhibit HIV-1IIIB (n ⫽ 10). These data represent
uNK clones from 15 individuals and bNK clones from 6 individuals. (B) Comparison of anti-HIV activities between CM from paired IL-12- plus
IL-15-stimulated and unstimulated uNK clones. These data show that stimulation of uNK cells resulted in an increase in HIV-1 inhibitory activity.
***, P ⬍ 0.001.
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FIG. 3. CM from uNK cells inhibit infection of PBMC and primary
FRT cells by HIV-1. (A) PHA-activated PBMCs were incubated with
media or with CM from IL-12- plus IL-15-stimulated uNK cells (uNK
CM), followed by infection with HIV-1 (IIIB ⫹). Following infection,
supernatant was collected from the PBMC cultures on days 3, 5, and 7
and added to TZM-bl cell cultures to quantify the amount of infectious
HIV-1. After 48 h of incubation with TZM-bl cells, ␤-Gal activity was
determined. Controls included supernatants from uninfected PBMCs
(⫺). These data are representative of three independent experiments
and are means ⫾ SEM (n ⫽ 4). ***, P ⬍ 0.001. (B) PHA-activated
endometrial cells from human uterine tissues were treated as in panel
A, and cell-free supernatants collected on days 3 and 5 were tested for
the presence of infectious HIV using TZM-bl reporter cells. Results
are shown as means ⫾ SEM (***, P ⬍ 0.001) and represent three
independent experiments, and samples from different donors were
used in each experiment.

cells secrete molecules that prevent HIV-1 infection of PBMCs
or primary FRT cells, we tested the ability of CM from activated uNK clones to inhibit HIV-1IIIB infection of PHA-activated PBMCs and FRT cells. PBMCs and primary FRT cells
were stimulated with PHA for 24 h to increase the efficiency of
HIV infection. CM from uNK cell clones was added to these
cells for 1 h, followed by incubation with HIV-1IIIB for an
additional 2 h. At days 3, 5, and 7 postinfection, cell-free
supernatants were collected and the presence of infectious
virus was assessed using TZM-bl reporter cells. As shown by
the data in Fig. 3, culturing the primary cells with CM from
uNK clones resulted in a significant reduction in HIV-1 production by these primary cells compared to cells cultured with
medium alone. These data show that uNK cells can produce
soluble factors that can inhibit the infection of primary cells
from the tissues where uNK cells reside.
uNK cells that inhibited HIV-1 infection produced CXCL12
and not IFN-␥. The ability of bNK cells to inhibit HIV-1
infection of target cells has been attributed to the production
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of chemokines and cytokines, including IFN-␥ (3, 16, 46). To
determine whether the anti-HIV activity of uNK cell secretions
was due to IFN-␥, we measured IFN-␥ amounts in CM from
uNK cell clones and compared IFN-␥ production in CM with
the anti-HIV-1 activity of CM. As seen in Fig. 4A, CM with
large amounts of IFN-␥ negatively correlated with anti-HIV
activity, and those that had small amounts of IFN-␥ had significantly higher anti-HIV activity (P ⬍ 0.001). CXCR4 is a
coreceptor required for infection by X4-tropic HIV-1, and
CXCL12 (SDF-1␣) is a chemokine that could block CXCR4
on CD4⫹ target cells (4). Because uNK cells preferentially
inhibited X4-tropic HIV viruses and uNK cells have been
found to secrete larger amounts of CXCL12 than bNK cells
(41), we hypothesized that the inhibitory activity in the CM
from activated uNK clones could be due to the secretion of
CXCL12. We measured the amounts of CXCL12 in uNK CM
and correlated these to anti-HIV activity. We observed that
uNK CM that demonstrated anti-HIV activity had significantly
larger amounts of CXCL12 than CM that showed no anti-HIV
activity (P ⬍ 0.001) (Fig. 4B). CM from bNK clones, however,
contained very small amounts of CXCL12, and these supernatants had no anti-HIV activity. Analysis of uNK samples, including primary expanded uNK cells from two individuals
showed that uNK cells which secreted large amounts of
CXCL12 produced little IFN-␥, and those that produced little
CXCL12 secreted large amounts of IFN-␥ (Fig. 4C). These
data suggest that production of these cytokines by uNK cells
may be from different functional uNK subsets (Fig. 4C).
Neutralizing CXCL12 abolishes uNK cell-mediated HIV-1
inhibition. The anti-HIV activity of CXCL12 is attributed to its
ability to inhibit viral entry via CXCR4 (4, 32), and CXCL12 is
produced by a number of cell types in humans, including NK
cells in the FRT (1, 41). To establish whether the anti-HIV
activity of uNK cells was due primarily to CXCL12 production,
we neutralized CXCL12 with CXCL12-specific antibodies in
the CM from cytokine-activated uNK cells and reassessed antiHIV activity. The data demonstrate that neutralizing CXCL12
abrogated the anti-HIV activity of the uNK CM, whereas the
use of an isotype control IgG had no effect (Fig. 5). TZM-bl
cells treated directly with either the CXCL12 blocking antibody or the isotype control IgG demonstrated no activation of
the HIV-1 LTR. Thus, one factor that can mediate anti-HIV
activity from uNK cells is production of CXCL12.
Anti-HIV activity is not confined to a known NK cell subset.
It has been reported that mucosal (tonsillar and gut) NK cells
can be differentiated into IL-22-producing NK cells (NK-22
cells) following IL-23 stimulation and that these NK cells do
not produce IFN-␥ (8). Because we found that CXCL12-secreting uNK clones had anti-HIV activity while IFN-␥-expressing uNK clones did not, we tested whether the uNK cells with
anti-HIV activity may be similar to these NK-22 cells. However, IL-22 was not found in CM from uNK cells cultured in
the presence or absence of IL-23 or IL-12 and IL-15 (data not
shown). These data were consistent with gene microarray data
that showed that freshly isolated uNK cells did not express
genes coding for IL-22, RORc, or NKp44 (data not shown),
which are genes known to be expressed by NK-22 cells. We
examined whether the anti-HIV activity of uNK cells could be
defined by a particular subset of NK cells by determining the
expression of CD4, CD8, CD16, CD25, CD38, CD57, CD69,
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FIG. 4. uNK cells that inhibited HIV-1 infection produced CXCL12 and not IFN-␥. (A) Cell-free uNK CM from clones that demonstrated
anti-HIV- activity (⫹) or lacking anti-HIV-1 activity (⫺) were analyzed for IFN-␥. There was a negative correlation between anti-HIV-1 activity
and amounts of IFN-␥. ***, P ⬍ 0.001 (n ⬎ 6 uNK clones). (B) CM from uNK and bNK clones were analyzed for the presence of CXCL12. There
was a positive correlation between CXCL12 production and anti-HIV-1 activity. ***, P ⬍ 0.001 (n ⫽ 8). Data are shown as means ⫾ SEM.
(C) Comparison between amounts of CXCL12 and IFN-␥ in uNK CM. These data show that uNK CM with large amounts of CXCL12 had small
amounts of IFN-␥ and vice versa. Statistical analysis was performed using the Mann-Whitney U test.

CD94, CD158b, NKB1, NKG2D, NKp30, and NKp80 and
compared these to the presence or absence of anti-HIV activity. As shown in Table 1, there was no correlation between the
expression of these molecules and anti-HIV activity of the
individual uNK clones.
DISCUSSION

FIG. 5. Neutralizing CXCL12 abrogates uNK cell anti-HIV activity. (A) uNK clones were stimulated with IL-12 plus IL-15 for 3 days,
and uNK CM (black bars) or culture medium (open bars) was preincubated with or without CXCL12 neutralizing antibodies or the isotype
control (IgG). This mixture was then added to TZM-bl cells for 1 h
before infecting the cells with HIV-1IIIB. ␤-Gal expression was determined after 48 h. (B) uNK CM from four different individuals were
treated in four different experiments as in panel A, and the data were
normalized to media (M). Values represent means ⫾ SEM. *, P ⬍
0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001 (n ⫽ 4). The y axis shows RLU
values, converted into percentages with “media” as 100%. Statistical
analysis was performed using the Mann-Whitney U test.

NK cells in blood can directly kill HIV-1-infected targets
though cell-to-cell contact or through the secretion of CC
chemokines that block CCR5 HIV-1 coreceptors (5, 26, 37).
However, HIV-1 is predominantly transmitted heterosexually
(34), and the primary entry site of virus is through the mucosa
of the FRT. Moreover, NK cells present in the FRT are unique
and distinct from those found in the peripheral blood (28, 31).
We therefore examined whether uNK cells can mediate antiHIV activity. In this study, we activated uNK cells with IL-12
and IL-15 as these are proinflammatory mediators which are
present within the human endometrium, produced by macrophages during an initial phase of an infection, and have been
shown to increase the cytolytic activity of NK cells (11, 25). Our
study demonstrates that uNK cells secrete soluble mediators
that exhibit anti-HIV activity for X4-tropic strains of HIV-1
and that this anti-HIV activity correlates with the amount of
secreted CXCL12 but not IFN-␥.
Although the anti-HIV effects of bNK cells have been reported by others (26, 37, 43, 46), the ability of uNK cells from
the FRT to secrete soluble mediators that inhibit HIV-1 infection has not been previously described. To the best of our
knowledge, this study is the first showing that CM from uNK
cells blocks HIV-1 infection of target cells. We found that bNK
cell CM did not inhibit HIV infection under similar experimental conditions. In contrast, previous studies have shown
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TABLE 1. Phenotype of uNK cells and anti-HIV-1 activity
Expression ofb:
ID no.

a

35-20
39-1
39-2
39-23
41-4
41-6
41-7
47-6
47-12
47-32
49-4
49-23
49-45
50-39
50-45
50-50
50-59
a
b

CD4, CD11c, CD38,
CD158b, or NKB1

CD38 CD45

CD8

CD16

NKG2D

NKp30

NKp80

Anti-HIV
activity

ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ND
ND
ND
ND

ⴙⴙ
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
ND
ND
ND
ND

ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
⫹⫹
ⴚ
⫹
ⴚ
ⴚ
⫹
⫹⫹
ⴚ
ⴚ
⫹

ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
ⴚ
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ⴚ
ⴚ
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ⴚ
⫹⫹
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⫹

⫹⫹
⫹
⫹
⫹⫹
⫹⫹
⫹⫹
⫹
⫹⫹
⫹
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⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹

⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹

⫹
⫹⫹
⫹⫹
⫹⫹
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

No
No
Yes
Yes
Yes
No
Yes
No
Yes
No
No
No
Yes
Yes
Yes
No
Yes

The identification (ID) numbers shown represent uNK clones from six different individuals: 35, 39, 41, 47, 49, and 50.
⫺, ⫹, and ⫹⫹, absence, low, and high expression, respectively. ND, not done.

that supernatants from NK cell cultures (both primary NK cells
and NK cell lines YTS and NK 92) inhibited HIV activation in
chronically HIV-infected immune cells (PBMCs) from HIVinfected subjects (46). In the present study, we used NK cell
clones and uninfected TZM-bl cells, PBMCs, and primary endometrial cells to measure the inhibitory effects of HIV infection and found that CM from bNK cells lacked the ability to
inhibit HIV-1 infection of target cells. These observed differences between uNK and bNK cells are likely due to the fact
that bNK and uNK cells are phenotypically and functionally
distinct NK cell subsets (15, 31). While the anti-HIV-1 activity
shown in some uNK clones was modest, a limited number of
NK cells were used in these experiments. Moreover, NK cells
are present in large numbers in the human FRT (31); thus, we
believe that the anti-HIV activity in vivo will be biologically
relevant.
NK cells are present in the human FRT, where they play a
critical role during implantation as well as in conferring protection against potential pathogens (14, 20, 22, 42). Our studies
used uNK cells isolated from reproductive tissues from patients undergoing hysterectomy for benign conditions. To obtain sufficient numbers of fresh uNK cells for these studies, the
uNK cells were cloned and expanded in the presence of IL-2.
Although it is possible for the uNK cell clones to express
effector functions that differ from primary uNK cells, we have
found that uNK cell clones are quite similar to activated primary uNK cells in many effector functions (15). In this study,
we demonstrated that a significant proportion of the uNK
clones secrete soluble mediators that inhibit HIV infection, an
activity that is enhanced upon cytokine activation and that is
blocked by neutralizing antibody to CXCL12. The ability of
anti-CXCL12 antibody to block the anti-HIV activity of uNK
CM demonstrated that the anti-HIV activity was likely due to
CXCL12. Furthermore, this inhibitory activity was effective
against both laboratory-adapted as well as primary X4 HIV-1
strains, but was not effective at preventing an infection with an
R5-tropic strain of HIV-1. Moreover, CM from cytokine-acti-

vated bNK cells did not have anti-HIV activity against any of
the viruses tested. Other studies have shown that noncytolytic
bNK cells have anti-HIV activity that is limited to R5, but not
X4, HIV-1 strains (17, 26, 37).
CXCL12 is the natural ligand for the chemokine receptor
CXCR4, and this chemokine can effectively block the entry of
X4-, but not R5-tropic viruses. The blocking activity of this
chemokine is consistent with our data in which we show that
the anti-HIV activity was limited to uNK cells that produced
larger amounts of CXCL12 and that the anti-HIV effect was
restricted to X4 viruses. Marechal et al. reported that CXCL12
has dual role in HIV-1 in that it can block the entry of the X4
strain of HIV-1 by binding to CXCR4 and also can increase
HIV replication through augmenting HIV LTR transcription
(29). Thus, CXCL12 may have competing roles during infection so that a large amount of CXCL12 may block X4-tropic
strains, but it may enhance replication of R5-tropic strains of
HIV. In addition, there may be other factors present in uNK
CM that contribute to inhibition of HIV-1 infection. The data
show that CXCL12 is required, but we cannot exclude that
other factors may be involved. R5-tropic viruses infect cells
based on CCR5 and other cell surface molecules. The mechanisms that regulate how different R5-tropic viruses infect different cell types remain unclear. The data presented showed
that uNK cells did not inhibit HIV-1BaL infection, but it cannot
be concluded that uNK cells are unable to affect infection by
other R5-tropic viruses. It is possible that uNK cells may prevent (or enhance) infection by other R5-tropic viruses by
mechanisms as yet undiscovered.
HIV-1 that is sexually transmitted is typically R5 tropic,
although the mechanism responsible for the selective transmission of R5 and the inhibition of X4 is not well characterized.
Whether this is due in part to the susceptibility of X4-tropic
strains to the host’s mucosal immune cell defenses within mucosal tissue sites or to selective virulence of R5-tropic strains is
not yet resolved. In contrast to reports by others (37, 46), our
study showed that the presence of large amounts of IFN-␥ did
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not correlate with anti-HIV activity, suggesting that the ability
of uNK cells to inhibit HIV is independent of IFN-␥ (26). It is
likely that there is heterogeneity within the population of uNK
cells, so that some uNK cell clones are able to mediate
CXCL12 production, while others can produce IFN-␥. Thus,
depending on their differentiation state, some uNK cells may
produce CXCL12 and inhibit HIV-1, while others lack the
ability to secrete this chemokine. Unique subsets of NK cells
with different effector potential have been reported. Recently,
a mucosal NK cell subset that expresses NKp44 was found in
the tonsil and gut that produce IL-22 but not IFN-␥ upon
stimulation (8). Our findings in the present study that uNK
cells did not produce IL-22 upon stimulation or express cell
surface proteins or transcription factors associated with this
unique mucosal NK cell subset suggest that uNK cells are
unique with a different effector potential from those found at
other mucosal sites. It has been shown that human bNK cells
can be differentiated in vitro into cell subsets with different
patterns of cytokine secretion: an NK1 subset that releases
IFN-␥ and an ⌵⌲2 subset that secretes type 2 cytokines, including IL-5 and IL-13 (12, 27, 40).
In summary, this report demonstrates that uNK cells can
be induced to secrete soluble factors that can inhibit HIV-1.
This anti-HIV activity is specific for X4-tropic strains, is
increased by cytokine activation, and is mediated by
CXCL12. These findings imply that uNK cells may play a
role in the protection against HIV-1 within the FRT and
that modulating uNK cells with inflammatory cytokines may
augment this antiviral activity.
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